Additionally, S-palmitoylation differentially affects mTOR signaling depending on cancer type: in renal cell carcinoma, ZDHHC2 enhances AGK S-palmitoylation, leading to AKT-mTORC1 activation [175], whereas in BrCa, ZDHHC22 reduces mTOR stability, thereby suppressing AKT-mTOR signaling [176]. The gene discussed is MTOR; the disease is cancer.